Public Joint-Stock Company "Artgen Biotech" (formerly Human Stem Cells Institute), a biotechnology firm founded in 2003 and headquartered in Moscow, Russia, develops, researches, and markets proprietary products and services in regenerative medicine; bio-insurance; medical and reproductive genetics; gene therapy; and biopharmaceutics. The company operates cord blood stem cell banking through its Gemabank subsidiary, the largest family bank in Russia and the CIS; reproductive cell and tissue banking via Reprobank for personal storage and donation services; gene-therapy drugs such as those treating peripheral artery disease; cell technologies for skin repair from aging damage; and Histograft, a gene-activated osteoplastic material. It primarily serves patients and healthcare providers in Russia, with a focus on socially significant and orphan diseases through an internal ecosystem of biotech subsidiaries at various development stages. In July 2023, the company rebranded from Human Stem Cells Institute to Artgen Biotech, unveiling a new corporate identity, logo, and website (artgen.ru) to better reflect its expanded role as a strategic investor fostering platform technologies, new drugs, medical devices, and healthcare efficiency initiatives. Artgen Biotech trades on the Moscow Exchange under ticker ISKJ.ME and continues to advance biobanking, genetic research, and innovative biomedicine solutions.